Dr. Grace A. Mccomsey, MD
Infectious Disease (Infectious Disease Physician)
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
OH license 35-064769 · OH license 35064769 -
Pediatric Infectious Diseases Physician
OH license 35-064769
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
Medical groups
- University Hospitals Medical Group Inc (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 59 |
| Atorvastatin Calcium Other prescribers in Cleveland, OH | 35 |
| Tivicay (dolutegravir sodium) | 29 |
| Descovy (emtricitabine/tenofov alafenam) | 24 |
| Omeprazole Other prescribers in Cleveland, OH | 20 |
| Cabenuva (cabotegravir/rilpivirine) | 19 |
| Lamivudine | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 14 payments worth $25,994 in total to this clinician.
| GlaxoSmithKline, LLC. | $18,071 |
|---|---|
| Merck Sharp & Dohme LLC | $4,443 |
| Gilead Sciences, Inc. | $3,480 |
| Consulting Fee | $25,968 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Aug 22, 2025 | Consulting Fee | $3,998 |
| GlaxoSmithKline, LLC. Dec 5, 2025 | Consulting Fee | $2,600 |
| GlaxoSmithKline, LLC. Oct 30, 2025 | Consulting Fee | $2,438 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Consulting Fee | $2,275 |
| GlaxoSmithKline, LLC. Dec 5, 2025 | Consulting Fee | $2,275 |
| GlaxoSmithKline, LLC. May 7, 2025 | Consulting Fee | $2,243 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,243 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $1,860 |
| Gilead Sciences, Inc. Mar 6, 2025 | Consulting FeeCompany’s description;4147470;VEM US;10045678 | $1,740 |
| Gilead Sciences, Inc. Mar 31, 2025 | Consulting FeeCompany’s description;4147551;VEM US;10045678 | $1,740 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 5, 2025 | Consulting Fee | $2,600 |
| GlaxoSmithKline, LLC. Dec 5, 2025 | Consulting Fee | $2,275 |
| Merck Sharp & Dohme LLC Dec 5, 2025 | Education ENFLONSIA · INFECTIOUS DISEASE · in-kind | $25.70 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Consulting Fee | $2,275 |
| GlaxoSmithKline, LLC. Oct 30, 2025 | Consulting Fee | $2,438 |
| GlaxoSmithKline, LLC. Aug 22, 2025 | Consulting Fee | $3,998 |
| Merck Sharp & Dohme LLC Aug 6, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $930 |
| GlaxoSmithKline, LLC. May 7, 2025 | Consulting Fee | $2,243 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,243 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $1,163 |
| Gilead Sciences, Inc. Mar 31, 2025 | Consulting FeeCompany’s description;4147551;VEM US;10045678 | $1,740 |
| Merck Sharp & Dohme LLC Mar 17, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $465 |
| Gilead Sciences, Inc. Mar 6, 2025 | Consulting FeeCompany’s description;4147470;VEM US;10045678 | $1,740 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $1,860 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,261 in research payments for these studies, mostly to the institutions running them.
- A phase 23 interventional safety pharmacokinetics and efficacy openlabel multicenter singlearm study to investigate orally administered PF07321332 nirmatrelvirritonavir in nonhospitalized symptomatic pediatric partici…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.